Sze H, Blanchard P, Ng WT, Pignon JP, Lee AW. Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies. Hematol Oncol Clin North Am. 2015 Dec. 29 (6):1107-22. [QxMD MEDLINE Link].
Moretto F, Rampino M, Munoz F, Ruo Redda MG, Reali A, Balcet V, et al. Conventional 2D (2DRT) and 3D conformal radiotherapy (3DCRT) versus intensity-modulated radiotherapy (IMRT) for nasopharyngeal cancer treatment. Radiol Med. 2014 Aug. 119 (8):634-41. [QxMD MEDLINE Link].
Chen YP, Tang LL, Zhang WN, Mao YP, Chen L, Sun Y, et al. Prognostic Value and Grading of MRI-Based T Category in Patients With Nasopharyngeal Carcinoma Without Lymph Node Metastasis Undergoing Intensity-Modulated Radiation Therapy. Medicine (Baltimore). 2015 Oct. 94 (43):e1624. [QxMD MEDLINE Link].
Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19. 381 (12):1124-1135. [QxMD MEDLINE Link].
Bae WK, Hwang JE, Shim HJ, Cho SH, Lee JK, Lim SC, et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol. 2010 Feb. 65 (3):589-95. [QxMD MEDLINE Link].
Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov. 17 (11):1509-1520. [QxMD MEDLINE Link].
Al-Sarraf M, LeBlanc M, Giri PG, et al. Superiority of five year survival with chemo-radiotherapy (CT-RT) vs radiotherapy in patients (Pts) with locally advanced nasopharyngeal cancer (NPC). Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III Study: Final Report. Presented at: Annual Meeting of ASCO; 2001.
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr. 16(4):1310-7. [QxMD MEDLINE Link].
Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005 Oct 1. 23(28):6966-75. [QxMD MEDLINE Link].
Dechaphunkul T, Pruegsanusak K, Sangthawan D, Sunpaweravong P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head Neck Oncol. 2011 Jun 5. 3:30. [QxMD MEDLINE Link].
Pazdur R, Wagman L, Camphausen K, et al, eds. Cancer Management: A Multidisciplinary Approach. 12th ed. Norwalk, Conn: CMP Healthcare Media LLC; 2009.
[Guideline] National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines. Head and Neck Cancers. Available at http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Version 2.2023 — May 15, 2023; Accessed: July 28, 2023.
Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, et al. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. J Clin Oncol. 2021 Oct 10. 39 (29):3273-3282. [QxMD MEDLINE Link]. [Full Text].
Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2002 Mar 15. 20(6):1593-9. [QxMD MEDLINE Link].
McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M, Siu LL. A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol. 2002 Oct. 38(7):686-90. [QxMD MEDLINE Link].
Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2005 Jul. 41(6):589-95. [QxMD MEDLINE Link].
Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001 Feb 15. 19(4):1088-95. [QxMD MEDLINE Link].
Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005 May 20. 23(15):3562-7. [QxMD MEDLINE Link].
Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May. 25(3):182-8. [QxMD MEDLINE Link].
Airoldi M, Pedani F, Marchionatti S, Gabriele AM, Succo G, Gabriele P, et al. Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori. 2002 Jul-Aug. 88(4):273-6. [QxMD MEDLINE Link].
Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol. 1999 Feb. 10(2):235-7. [QxMD MEDLINE Link].
Ciuleanu TE, Fountzilas G, Ciuleanu E, Plataniotis M, Todor N, Ghilezan N. Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study. J BUON. 2004 Apr-Jun. 9(2):161-5. [QxMD MEDLINE Link].
A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. Br J Cancer. 1990 Feb. 61(2):311-5. [QxMD MEDLINE Link]. [Full Text].
Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug. 10(8):1245-51. [QxMD MEDLINE Link].
Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992 Feb. 10(2):257-63. [QxMD MEDLINE Link].
Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul. 5(6):521-6. [QxMD MEDLINE Link].
Ma BB, Tannock IF, Pond GR, Edmonds MR, Siu LL. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer. 2002 Dec 15. 95(12):2516-23. [QxMD MEDLINE Link].
Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002 Aug. 13(8):1252-8. [QxMD MEDLINE Link].
Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005 May 20. 23 (15):3568-76. [QxMD MEDLINE Link].
Chen C, Wang FH, Wang ZQ, An X, Luo HY, Zhang L, et al. Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol. 2012 Nov. 48 (11):1146-51. [QxMD MEDLINE Link].
Zhang L, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol. 2008 Jan. 61(1):33-8. [QxMD MEDLINE Link].
Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, Chan TM, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002 Aug. 13(8):1252-8. [QxMD MEDLINE Link].
Au E, Tan EH, Ang PT. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer. Ann Oncol. 1998 Mar. 9(3):327-9. [QxMD MEDLINE Link].
Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 1994 Jul. 5(6):533-7. [QxMD MEDLINE Link].
Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996 May. 14(5):1672-8. [QxMD MEDLINE Link].
Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 1999 Oct. 81(3):457-62. [QxMD MEDLINE Link]. [Full Text].
Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004 Sep. 40(14):2071-6. [QxMD MEDLINE Link].
Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol. 2007 Jul. 37(7):477-81. [QxMD MEDLINE Link].
Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer. 2010 Jun 8. 102 (12):1687-91. [QxMD MEDLINE Link]. [Full Text].
Yeo W, Leung TW, Chan AT, Chiu SK, Yu P, Mok TS, et al. A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. Eur J Cancer. 1998 Dec. 34(13):2027-31. [QxMD MEDLINE Link].
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016 Oct 8. [QxMD MEDLINE Link]. [Full Text].
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 20. 35 (36):4050-4056. [QxMD MEDLINE Link].